Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7 versus 14 days of ciprofloxacin for male urinary tract infection with systemic involvement
2025-524703-76-00Phase 3Authorised
- Sponsor
- UZ Brussel
- Start
- May 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ciprofloxacin in urinary tract infection (UTI) (2 arms), sponsored by UZ Brussel. Primary endpoint: Clinical cure rate. Planned start May 2026; status: authorised.
02
Drugs
ciprofloxacin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on 2025-524703-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524703-76-00.